0001415889-24-004417.txt : 20240220 0001415889-24-004417.hdr.sgml : 20240220 20240220171524 ACCESSION NUMBER: 0001415889-24-004417 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240215 FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stewart Jeffrey Ryan CENTRAL INDEX KEY: 0001761675 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24654849 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 form4-02202024_050210.xml X0508 4 2024-02-15 0001551152 AbbVie Inc. ABBV 0001761675 Stewart Jeffrey Ryan 1 N. WAUKEGAN ROAD NORTH CHICAGO IL 60064 false true false false EVP, CHIEF COMMERCIAL OFFICER 0 Common Stock, $0.01 par value 2024-02-15 4 A 0 33042 0 A 93983 D Common Stock, $0.01 par value 2024-02-15 4 A 0 8810 0 A 102793 D Common Stock, $0.01 par value 2024-02-15 4 A 0 7840 0 A 110633 D Common Stock, $0.01 par value 2024-02-15 4 A 0 9268 0 A 119901 D Common Stock, $0.01 par value 1338 I By spouse in trust Option (Right to Buy) 0 2024-02-15 4 A 0 39085 0 A 2025-02-15 2034-02-14 Common Stock 39085 39085 D Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. The reporting person disclaims beneficial ownership of all securities held by his spouse. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,029 on February 15, 2025, 13,028 on February 15, 2026, and 13,028 on February 15, 2027. T.O. Odutayo, attorney-in-fact for Jeffrey R. Stewart 2024-02-20 EX-24 2 ex24-02202024_050210.htm ex24-02202024_050210.htm


POWER OF ATTORNEY


Jeffrey R. Stewart constitutes and appoints PERRY C. SIATIS,  EMILY A. WEITH, and T.O. ODUTAYO, and each of them individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for the undersigned and in the undersigned's name, place and stead, to prepare and sign any and all Securities and Exchange Commission  ("SEC") Notices of Proposed Sales of Securities pursuant to Rule 144 under the Securities  Act of 1933, as amended (the “Securities Act”), on Form 144, any and all SEC statements on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all other forms and reports required or permitted to be filed or signed by the undersigned under the Securities Act or the Exchange Act, to the extent permitted by law, as well as a Form ID and any other documents necessary to obtain codes and passwords necessary to make electronic filings, and any amendments or successors to such forms or reports, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite, necessary or desirable to be done under said Rule 144 and Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.


A copy of this power of attorney shall be filed with the SEC.  The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to file Forms 144, 3, 4, or 5 or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.




Date:  July 12, 2023


/s/ Jeffrey R. Stewart

Jeffrey R. Stewart



AbbVie Inc.

1 N. Waukegan Road

North Chicago, IL   60064